Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

Inclusion Criteria: * Geographic atrophy (GA) secondary to AMD with no evidence of prior to active choroidal neovascularization (CNV) in the study eye. * BCVA in the study eye must be between 4 and 58 Early Treatment of Diabetic Retinopathy Study (EDTRS) letters (20/800 to 20/80; 0.025-0.25) * Subjects must be willing to take IMT and willing to discontinue any medication that has a known strong interaction with tacrolimus or mycophenolate mofetil (MMF) Exclusion Criteria: * Macular atrophy due to causes other than AMD * Other sight-threatening ocular disease * Current or prior history of optic neuropathy, retinal dystrophy, retinitis pigmentosa, chorioretinitis, vasoocclusive disease, retinal vascular disease or retinal degenerative disease OTHER than AMD * History of uveitis * History of allergic reaction to sulfa drugs * Solid organ or bone marrow transplant recipient * History of malignancy within the previous 5 years (except for BCC (basal cell carcinoma), SCC (squamous cell carcinoma) or in-situ cervical) * History of myocardial infarction with past 12 months * History of clinically significant cardiac dysrhythmia * History of diabetes mellitus, bowel disease, tuberculosis * Prior treatment for non-exudative AMD * Intraocular, refractive or cataract surgery in the last 12 weeks * Prior retinal surgery, vitrectomy, macular laser photocoagulation, external beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery (except cataract surgery) * Receipt of gene transfer of cell transplant therapy in a prior clinical trial * Participation in any other interventional clinical trial within the last 12 weeks